Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion
NCT ID: NCT06416241
Last Updated: 2024-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
51 participants
INTERVENTIONAL
2017-01-01
2024-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Aflibercept has been found to improve visual acuity and reduce macular thickness in pivotal trials.
The purpose of this study was to evaluate the efficacy and safety of intravitreal aflibercept in real-world, using a patient-fitted treatment regimen. Additionally, imaging parameters have been assessed before and after treatment with intravitreal aflibercept.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO
NCT02800642
Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion
NCT02645747
Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)
NCT02040220
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
NCT01012973
Navigated Laser In Branch Retinal Vein Occlusion Study
NCT03651011
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Eylea 2.0mg/0.05ml
EYLEA 2 MG in 0.05 ML Injection
Intravitreal injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EYLEA 2 MG in 0.05 ML Injection
Intravitreal injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients \>18 years of age, who are diagnosed with macular edema secondary to CRVO who are scheduled to be treated with intravitreal aflibercept in real-life conditions
* BCVA of Snellen of 20/40 to 20/200 in the study eye
Exclusion Criteria
* Any prior ocular treatment in the study eye for macular edema secondary to CRVO.
* Prior systemic anti-VEGF or corticosteroid therapy, within the last 3 months before enrollment to the study.
* Any active or previous inflammation, ocular trauma
* Uncontrolled glaucoma (IOP\>30 mmHg)
18 Years
95 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Athens
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Irini Chatziralli
Associate Professor in Ophthalmology
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
699/2019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.